Satellite Symposia

THSNA is happy to host the 2020 Satellite Symposium Program. Please note the following:

  • Each event is planned independently of the THSNA program committee and THSNA does not endorse the programming content.
  • You must be a THSNA registrant in order to attend any satellite symposia.
  • There is no cost to attend these symposia.
  • All symposia occur during a meal and food will be provided.
  • If a pre-registration link is not provided, all admittance will be on a first-come, first-served basis.
  • Any pre-registrants not present at the session room door 10 minutes prior to the start of the program will be removed from the pre-registrant list.

Additional details for these corporate workshops will be posted here as they become available.

Sunday, August 23

Bayer Corporate Lunch Symposia

Sponsored By: Bayer
Chicago Ballroom 7, 12:15-1:45 pm

Takeda Lunch Symposia: Hemophilia A Without Inhibitors: Personalizing Therapy With Factor VIII Prophylaxis

Provided by Clinical Care Options, LLC. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Chicago Ballroom 6, 12:15-1:45 pm

A 1.5-hour satellite lunch symposium during THSNA with 3 expert faculty highlighting advances in individualized therapy with Factor VIII prophylaxis in patients with hemophilia A. CME, CE and CPE credits will be offered. To pre-register visit:

Alnylam Corporate Dinner Symposia

Sponsored By: Alnylam
Chicago Ballroom 7, 6:30- 8:30pm

Pfizer Dinner Symposia: Perspectives On Hemophilia B Care In An Era Of Advanced Therapeutics And Extravascular FIX Science: Past, Present And Future Considerations

Sponsored By: Pfizer
Chicago Ballroom 6, 6:30- 8:30pm

Monday, August 24

Janssen Breakfast Symposium: Evidence-Based Approach to Anticoagulation Therapy for DVT/PE

Supported by: Janssen Pharmaceuticals, Inc.
Chicago Ballroom 7, 7:00- 7:45am

This lecture will discuss treatment options for patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and how they may reduce the risk of recurrent thrombotic events. Speaker: Samuel A. Berkman, MD, FACP Beverly Hills, CA

Sanofi Genzyme Breakfast Symposia: A Breakthrough in aTTP Treatment

Sponsored By: Sanofi Genzyme
Chicago Ballroom 6, 7:00- 7:45am

This program will demonstrate the importance of rapid diagnosis and treatment of acquired thrombotic thrombocytopenic purpura (aTTP) with a focus on new treatment options for adult patients with aTTP

CSL Behring Lunch Symposia: A Dialogue on Elevating Patient Care for Hemophilia B Patients

Supported by: CSL Behring
Chicago Ballroom 6, 12:15-1:45 pm

During this educational symposium Dr. Tammuella Chrisentery-Singleton will take attendees through a journey of the current standard of care for patients with hemophilia B. Audience members will be encouraged to consider whether a “satisfied” patient is an appropriately protected patient. Attendees will hear more about recent advancements in hemophilia treatments that redefine the standard of care and empower patients to optimize their hemophilia treatment. *Lunch will be provided

Novo Lunch Symposia: Double Feature: Obesity in Hemophilia and a New Treatment Option for Hemophilia A

Sponsored By: Novo Nordisk
Chicago Ballroom 7, 12:15-1:45 pm

The first part is an interactive program discussing the importance of managing obesity in the hemophilia community.  Managing obesity is one of the toughest challenges for health care professionals in general and is often overlooked. This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia. Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered. In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a new factor VIII extended half-life product.

Genentech Dinner Symposia: Get Your Game On: Hemophilia A Edition

Supported by: Genentech, Inc.
Chicago Ballroom 7, 6:30- 8:30pm

Join us for an evening of dinner, discussion, and good-old-fashioned games! Play your hand at some classic trivia and friendly competition during a lively discussion of panelists and community members sharing their experiences treating or living with hemophilia A. Don’t miss this opportunity to tap into your competitive side and learn more about a treatment option for people with hemophilia A, followed by a live Q&A. The event will be led by Shannon Meeks, MD, and feature Michael Callaghan, MD, Jennifer Maahs, NP, and Louis C., a person living with hemophilia A.

Sanofi Genzyme Dinner Symposia: Beyond ABRs: HCP and Patient Perspectives in an Evolving Hemophilia Treatment Landscape

Sponsored By: Sanofi Genzyme
Chicago Ballroom 6, 6:30- 8:30pm

Join us for a discussion about helping to meet the needs of people living with hemophilia A and B in an evolving treatment landscape. This symposium will include both patient and HCP perspectives on how clinical data translate into the real world. Following a presentation of clinical data, HCPs and patients will share their experience of hemophilia management in today’s treatment paradigm. Topics will include innovative approaches to patient engagement and the integration of ultrasound, with an emphasis on joint bleed protection.

Tuesday, August 25

Octapharma Breakfast Product Theater: Final Results from the NUWIQ® PUP Study: Inhibitor Rates & Beyond

Sponsored By: Octapharma
Chicago Ballroom 7, 7:00- 7:45am

Dr. Ellis Neufeld will present final data from the NuProtect study. Octapharma USA is the sponsor of this program. NuProtect is a prospective, multinational, open-label, phase III study to assess the immunogenicity, efficacy and safety of NUWIQ® Antihemophilic Factor (Recombinant), a human cell line-derived rFVIII, in previously untreated patients (PUPs) with severe hemophilia A. NuProtect is the largest prospective study of a single FVIII product in PUPs with hemophilia A, conducted in 105 PUPs followed for up to 100 exposure days. Final results showed a cumulative incidence of high-titer inhibitors of 17.6%. Dr. Neufeld will discuss these results in the context of the SIPPET study, in which the cumulative incidence of high-titer inhibitors was 28.4% in patients treated with rFVIII products derived from hamster cell lines, and 18.6% in those treated with plasma-derived FVIII. In addition, new data on efficacy from the study will be shared. The completion of NuProtect represents a major clinical milestone for NUWIQ and the hemophilia community. Presented by: Ellis Neufeld, MD, PhD, FAAP.

To register, visit:

Sanofi Genzyme Breakfast Symposia: Breaking the Barriers in Hemostasis

Sponsored By: Sanofi Genzyme
Chicago Ballroom 6, 7:00- 7:45am

This symposium will shed the light and appreciate advances in hemostasis. It will also help understand the science behind emerging treatment options and discuss how new therapies might improve the standard of care for people with hemophilia (PwH).